• Huntington’s disease is a genetic disorder that gradually destroys brain cells over the course of 10 to 30 years, typically starting between the ages of 35 and 50

• Phase 1b/2a will evaluate the safety of the treatment and provides hope for those with few options to slow the progression of the disease

• Clinical trial will enroll 21 people with early-stage Huntington’s disease, with 12 participants in a phase 1b dose-escalation group and nine in a phase 2a expansion group

UCLA scientists are calling for a large-scale initiative to understand how human cells influence one another — a missing layer of biology that could reveal how cellular interactions drive disease and inform new therapies.

A deep learning system (DL-T1b) leveraging digital pathology achieved strong performance (AUC 0.910) for predicting lymph node metastasis in T1b gastric cancer. Integration with six clinical risk factors into a nomogram further boosted predictive accuracy, offering a precise tool for personalized treatment decisions. This study establishes proof-of-concept for deep learning-based pathomics in early gastric cancer risk stratification.